Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses

Journal of Investigative Dermatology

Volumn 133, Issue 12, 2013, Pages 2706-2713

  Schellenbacher, Christina ^a   Kwak, Kihyuck ^b   Fink, Dieter ^c   Shafti Keramat, Saeed ^a   Huber, Bettina ^a   Jindra, Christoph ^a   Faust, Helena ^d   Dillner, Joakim ^e   Roden, Richard B S ^b   Kirnbauer, Reinhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^d LUND UNIVERSITY   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; ALUMINUM HYDROXIDE; CAPSID PROTEIN L2; PHOSPHORYL LIPID A; PROTEIN RG1; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEMALE GENITAL TRACT INFECTION; HIGH RISK PATIENT; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RABBIT; VACCINATION; VIRAL SKIN DISEASE; VIRION; VIRUS LIKE AGENT;

EID: 84887827859     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.253     Document Type: Article

References (41)

1. Alphs HH, Gambhira R, Karanam B et al. (2008) Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 105:5850-5
2. Bernard HU, Burk RD, Chen Z et al. (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-9
3. Bouwes Bavinck JN, Plasmeijer EI, Feltkamp MC (2008) beta-Papillomavirus infection and skin cancer. J Invest Dermatol 128:1355-8
4. Caldeira Jdo C, Medford A, Kines RC et al. (2010) Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 28:4384-93
5. Chandrachud LM, Grindlay GJ, McGarvie GM et al. (1995) Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology 211:204-8
6. Christensen ND, Kreider JW (1991) Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions. Virus Res 21:169-79
7. de Sanjose S, Quint WG, Alemany L et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-56
8. Gambhira R, Jagu S, Karanam B et al. (2007a) Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81:11585-92
9. Gambhira R, Karanam B, Jagu S et al. (2007b) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81: 13927-31
10. Hagensee ME, Yaegashi N, Galloway DA (1993) Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67:315-22
11. Handisurya A, Gambhira R, Schellenbacher C et al. (2009) Serological relationship between cutaneous human papillomavirus types 5, 8 and 92. J Gen Virol 90:136-43
12. Handisurya A, Rieger A, Bankier A et al. (2007) Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy. Br J Dermatol 157:788-94
13. Jagu S, Karanam B, Gambhira R et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101:782-92
14. Jenkins AL, Lang CM, Budgeon LR et al. (2003) Mucosally-derived HPV-40 can infect both human genital foreskin and cutaneous hand skin tissues grafted into athymic mice. Virus Res 93:109-14
15. Karagas MR, Nelson HH, Sehr P et al. (2006) Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 98:389-95
16. Karanam B, Peng S, Li T et al. (2010) Papillomavirus infection requires gamma secretase. J Virol 84:10661-70
17. Kawana K, Yoshikawa H, Taketani Y et al. (1999) Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73:6188-90
18. Kirnbauer R, Booy F, Cheng N et al. (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180-4
19. Kirnbauer R, Taub J, Greenstone H et al. (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67:6929-36
20. Kondo K, Ochi H, Matsumoto T et al. (2008) Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 80:841-6
21. Lally A, Casabonne D, Imko-Walczuk B et al. (2011) Prevalence of benign cutaneous disease among Oxford renal transplant recipients. J Eur Acad Dermatol Venereol 25:462-70
22. Longet S, Schiller JT, Bobst M et al. (2011) A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 85:13253-9
23. McLaughlin-Drubin ME, Christensen ND, Meyers C (2004) Propagation, infection, and neutralization of authentic HPV16 virus. Virology 322:213-9
24. Munoz N, Bosch FX, Castellsague X et al. (2004) Against which human papillomavirus types shall we vaccinate and screen The international perspective. Int J Cancer 111:278-85
25. Nieto K, Weghofer M, Sehr P et al. (2012) Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One 7:e39741
26. Ohlschlager P, Osen W, Dell K et al. (2003) Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 77:4635-45
27. Parkin DM, Bray F, Ferlay J et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
28. Pastrana DV, Gambhira R, Buck CB et al. (2005) Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337:365-72
29. Roberts JN, Buck CB, Thompson CD et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13:857-61
30. Roden RBS, Yutzy WH, Fallon R et al. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270:254-7
31. Rose RC, Bonnez W, Reichman RC et al. (1993) Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67:1936-44
32. Rubben A, Kalka K, Spelten B et al. (1997) Clinical features and age distribution of patients with HPV 2/27/57-induced common warts. Arch Dermatol Res 289:337-40
33. Schellenbacher C, Roden R, Kirnbauer R (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83:10085-95
34. Senger T, Becker MR, Schadlich L et al. (2009) Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. J Virol 83:12692-701
35. Slupetzky K, Gambhira R, Culp TD et al. (2007) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25:2001-10
36. Smith LH, Foster C, Hitchcock ME et al. (1995) Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J Invest Dermatol 105:438-44
37. Suzich JA, Ghim S, Palmer-Hill FJ et al. (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553-7
38. Tjalma WA, Fiander A, Reich O et al. (2012) Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 132:854-67
39. Tumban E, Peabody J, Tyler M et al. (2012) VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One 7:e49751
40. Van Haalen FM, Bruggink SC, Gussekloo J et al. (2009) Warts in primary schoolchildren: prevalence and relation with environmental factors. Br J Dermatol 161:148-52
41. Zamora E, Handisurya A, Shafti-Keramat S et al. (2006) Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol 177:2662-70